Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis

Julianne Fava, Emily Stephan, Jessica Tansmore, Shahid Sheikh, Mariah Eisner, Kimberly J. Novak

Open source

DOI
10.1002/ppul.71749
Published
2026-07-28
Container
Pediatric Pulmonology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/ppul.71749,
  title = {Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis},
  author = {Julianne Fava and Emily Stephan and Jessica Tansmore and Shahid Sheikh and Mariah Eisner and Kimberly J. Novak},
  year = {2026},
  journal = {Pediatric Pulmonology},
  doi = {10.1002/ppul.71749},
  url = {https://doi.org/10.1002/ppul.71749}
}

RIS

TY  - JOUR
TI  - Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis
AU  - Julianne Fava
AU  - Emily Stephan
AU  - Jessica Tansmore
AU  - Shahid Sheikh
AU  - Mariah Eisner
AU  - Kimberly J. Novak
PY  - 2026
JO  - Pediatric Pulmonology
DO  - 10.1002/ppul.71749
UR  - https://doi.org/10.1002/ppul.71749
ER  - 

APA

Fava, J., Stephan, E., Tansmore, J., Sheikh, S., Eisner, M., & Novak, K. J. (2026). Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71749

Source records